Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973.
Between 1958 and 1973, 2412 women with epithelial ovarian carcinoma were treated at Radiumhemmet. Of these tumors, 14.5 per cent were of borderline malignancy. The 5-year relative survival rate was 34 per cent among the patients with true malignant tumor and 93 per cent in the borderline cases. Even in advanced stages (IIb-IV) the 5-year survival rate was 78 per cent in the borderline cases. Advanced stage and high age at diagnosis, true malignancy and tumors of serous, clear cell or anaplastic type were associated with poor prognosis. The 5-year relative survival rate of patients with epithelial ovarian carcinoma in an early stage improved during the period, from 67 to 81 per cent.
D000230:Adenocarcinoma / Q000601:surgery / Q000628:therapy*; D002288:Adenocarcinoma, Mucinous / Q000601:surgery / Q000628:therapy*; D002277:Carcinoma / Q000601:surgery / Q000628:therapy*; D004715:Endometriosis / Q000601:surgery / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D013223:Statistics as Topic; D013997:Time Factors
D008558:Melphalan